{
    "id": 17963,
    "fullName": "BCL2L1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BCL2L1 over exp indicates an over expression of the BCL2L1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 598,
        "geneSymbol": "BCL2L1",
        "terms": [
            "BCL2L1",
            "Bcl-X",
            "BCL-XL/S",
            "BCL2L",
            "BCLX",
            "PPP1R52"
        ]
    },
    "variant": "over exp",
    "createDate": "02/14/2016",
    "updateDate": "06/12/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic myeloid leukemia cell lines with elevated BCL2L1 (BCL-XL) expression were insensitive to S63845 in culture (PMID: 27760111).",
            "molecularProfile": {
                "id": 18292,
                "profileName": "BCL2L1 over exp"
            },
            "therapy": {
                "id": 4858,
                "therapyName": "S63845",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4521,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of BCL2L1 in human non-small cell lung cancer cells harboring BRAF V600E with YAP1 knockdown, resulted in resistance to Zelboraf (vemurafenib) in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18293,
                "profileName": "BCL2L1 over exp BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4523,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of BCL2L1 in human non-small cell lung cancer cells harboring BRAF V600E with YAP1 knockdown, resulted in resistance to Mekinist (trametinib) in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18293,
                "profileName": "BCL2L1 over exp BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18292,
            "profileName": "BCL2L1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18293,
            "profileName": "BCL2L1 over exp BRAF V600E YAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}